Through the deal, Regeneron says it aims to bolster its capabilities in genomics-driven drug discovery by integrating 23andMe's trove of over 15 million customer DNA profiles, collected via its ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Biotechnology company Regeneron buying 23andMe for $256 million By: Michelle Chapman, The Associated Press Posted: 8:00 AM CDT Monday, May. 19, 2025 Last Modified: 8:44 AM CDT Monday, May. 19, 2025 ...

(Reuters) -Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data from ...

(Reuters) -Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking investor worries as U.S. regulators denied ...

Regeneron Pharmaceuticals Inc. said on Monday it will buy genomics firm 23andMe Holding Co. for US$256-million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data ...